06/02/14 - 11:23 AM EDT
I'm sure Northwest Bio thought it would raise its profile with a booth the size of a small Illinois town, but from an investors' perspective, the company was simply the brunt of guffaws over the weekend for wasting a ridiculous amount of money.READ FULL POST
06/02/14 - 06:54 AM EDT
It's Monday, so we get to see how investors react to a full weekend's worth of cancer drug data presentations at the American Society of Clinical Oncology (ASCO) annual meeting.READ FULL POST
05/30/14 - 02:01 PM EDT
Featured data presentations from Eli Lilly, Pharmacyclics and Clovis Oncology on the Saturday menu for the biggest cancer conference in the world.READ FULL POST
05/28/14 - 10:37 AM EDT
Aspen Investments and Zoi Potsi, a resident of Cyprus, declared a 9.65% ownership stake in struggling obesity pill marketer Vivus this morning and say they want to buy the rest of the company for $640 million.READ FULL POST
05/27/14 - 06:07 PM EDT
The tumor response rate attributable to Northwest Biotherapeutics DCVax-Direct is zero. None of the 19 patients with advanced, metastatic cancers have responded to treatment with DCVax-Direct in an ongoing phase I clinical study.READ FULL POST
05/27/14 - 09:48 AM EDT
The New York Stock Exchange has placed Provectus' listing status under review, following Friday's PV-10 Breakthrough Therapy Designation debacle. The stock may re-open at some point today, or may not. And if Provectus does trade today, it may not trade for long.READ FULL POST
05/23/14 - 02:56 PM EDT
The FDA turned down Provectus BioPharmaceuticals' request to grant Breakthrough Therapy Designation (BTD) to its experimental skin cancer drug PV-10.READ FULL POST
05/23/14 - 08:46 AM EDT
PTC Therapeutics shares have doubled this morning on the surprising (I'd say shocking) news that European regulators recommended the conditional approval of Translarna as a new treatment for patients with Duchenne muscular dystrophy caused by so-called "nonsense" mutations.READ FULL POST
05/20/14 - 01:42 PM EDT
Provectus is supposed to hear back from the FDA this week about the request to grant PV-10 Breakthrough Therapy status for skin cancer. So far, Provectus has said nothing about the FDA's response.READ FULL POST
05/20/14 - 10:26 AM EDT
Japanese companies have a history of paying grossly inflated prices for U.S. assets, but the drug maker Eisai would have to be monumentally stupid -- and financially reckless -- to buy out its obesity drug partner Arena Pharmaceuticals.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.